Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.

Yin Y, Xiang J, Tang S, Chen J, Yu Q, Zhang B.

Medicine (Baltimore). 2016 Dec;95(49):e5488.

2.

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.

Eur J Cancer. 2016 Apr;57:31-8. doi: 10.1016/j.ejca.2015.12.029. Epub 2016 Feb 4.

PMID:
26851399
3.

[A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].

Xu H, Ma L, Xu W, Guan W, Wang B, Li G, Miao Y, Li L, Chen H, Yu J, Wang Y, Sun L, Yang L, Zhang D, Li F, Zhi X, Wang J, Xu J, Xu Z.

Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Nov 25;19(11):1271-1276. Chinese.

PMID:
27928798
4.

Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.

Yoo C, Ryu MH, Ryoo BY, Beck MY, Kang YK.

Invest New Drugs. 2013 Oct;31(5):1367-74. doi: 10.1007/s10637-013-9961-8. Epub 2013 Apr 17.

PMID:
23591629
5.

Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.

Wu X, Li J, Zhou Y, Mao Y, Luo S, He X, Wang L, Shen Y, Zhang H, Yang L, Zhang J.

Chemotherapy. 2018;63(6):301-307. doi: 10.1159/000493195. Epub 2019 Mar 5.

PMID:
30836365
6.

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

Zhuang W, Xie JD, Zhou S, Zhou ZW, Zhou Y, Sun XW, Yuan XH, Huang M, Liu S, Xin S, Su QB, Qiu HB, Wang XD.

Cancer Med. 2018 Feb;7(2):317-324. doi: 10.1002/cam4.1286. Epub 2018 Jan 7.

7.
8.

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK.

J Clin Oncol. 2010 Mar 20;28(9):1554-9. doi: 10.1200/JCO.2009.26.5785. Epub 2010 Feb 22.

PMID:
20177019
9.

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.

Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema AD, Steeghs N.

Clin Pharmacokinet. 2017 Mar;56(3):287-292. doi: 10.1007/s40262-016-0439-7.

PMID:
27435281
10.

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.

Liu J, Chen Z, Chen H, Hou Y, Lu W, He J, Tong H, Zhou Y, Cai W.

Int J Mol Sci. 2017 Mar 13;18(3). pii: E603. doi: 10.3390/ijms18030603.

11.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
12.

The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.

Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.

J Med Econ. 2015 Mar;18(3):241-8. doi: 10.3111/13696998.2014.991787. Epub 2014 Dec 5.

PMID:
25422992
13.

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.

Blanke CD, Rankin C, Corless C, Eary JF, Mulder K, Okuno SH, George S, Heinrich M.

Oncologist. 2015 Dec;20(12):1353-4. doi: 10.1634/theoncologist.2015-0295. Epub 2015 Nov 17.

14.
15.

Synchronous Large Gastrointestinal Stromal Tumor and Adenocarcinoma in the Stomach Treated with Imatinib Mesylate Followed by Total Gastrectomy.

Namikawa T, Munekage E, Munekage M, Maeda M, Yatabe T, Kitagawa H, Sakamoto K, Obatake M, Kobayashi M, Hanazaki K.

Anticancer Res. 2016 Apr;36(4):1855-9.

PMID:
27069170
16.
17.

[Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].

Raccah E, Merimsky O, Kuten A, Apter S, Catane R.

Harefuah. 2007 May;146(5):329-34, 408. Hebrew.

PMID:
17674545
18.

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.

Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W.

J Surg Oncol. 2006 Mar 15;93(4):304-11.

PMID:
16496358
19.

Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era.

Stiekema J, Kol S, Cats A, Yazdi AT, van Coevorden F, van Sandick JW.

Am J Clin Oncol. 2015 Oct;38(5):502-7. doi: 10.1097/COC.0b013e3182a78de9.

PMID:
24064754
20.

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

Ruka W, Rutkowski P, Szawłowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W.

Eur J Surg Oncol. 2009 Jan;35(1):87-91. doi: 10.1016/j.ejso.2008.01.003. Epub 2008 Mar 4.

PMID:
18289826

Supplemental Content

Support Center